Five Prime Therapeutics and Zai Lab Announce Exclusive License Agreement for FPA144 Anti-FGFR2b Antibody in Greater China and Global Strategic Development Collaboration
December 19, 2017 16:05 ET
|
Five Prime Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif. and SHANGHAI, China, Dec. 19, 2017 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (NASDAQ:FPRX), a biotechnology company discovering and developing innovative...
Five Prime Therapeutics to Present at BMO Capital Markets Prescriptions for Success Healthcare Conference
December 04, 2017 16:05 ET
|
Five Prime Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Dec. 04, 2017 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a biotechnology company discovering and developing innovative immuno-oncology protein...
Five Prime Therapeutics Presents Poster on FGFR2b Expression and Immune Signature in Urothelial Cancer at the Society for Immunotherapy of Cancer 32nd Annual Meeting
November 10, 2017 12:30 ET
|
Five Prime Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 10, 2017 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative...
Five Prime Therapeutics to Host Conference Call on November 11th to Review Cabiralizumab Phase 1a/1b Data to be Presented in Late Breaking Oral Presentation at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting
November 07, 2017 08:00 ET
|
Five Prime Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 07, 2017 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (NASDAQ:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative...
Five Prime Announces Third Quarter 2017 Results and Provides Business Update
November 06, 2017 16:05 ET
|
Five Prime Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 06, 2017 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative...
Five Prime Therapeutics Presents Preclinical Data Demonstrating Potent Anti-Tumor Activity with FPT155
October 30, 2017 08:00 ET
|
Five Prime Therapeutics, Inc.
Poster featured at 2017 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsCompany anticipates filing an IND for FPT155 in mid 2018 SOUTH SAN FRANCISCO, Calif., Oct. ...
Five Prime Therapeutics Announces Appointment of Aron Knickerbocker as CEO Effective January 1, 2018
October 23, 2017 16:05 ET
|
Five Prime Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 23, 2017 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative...
Five Prime Therapeutics to Announce Third Quarter 2017 Financial Results and Host Conference Call on November 6
October 19, 2017 16:05 ET
|
Five Prime Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 19, 2017 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (NASDAQ:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative...
Five Prime to Present Preclinical Data on FPT155 at the 2017 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
October 18, 2017 16:05 ET
|
Five Prime Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 18, 2017 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative...
Five Prime Announces Cabiralizumab Phase 1a/1b Data Abstract Selected for Late Breaking Oral Presentation at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting
October 11, 2017 16:15 ET
|
Five Prime Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 11, 2017 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative...